uploads/2017/11/Eliquis.png

An Update on Bristol-Myers Squibb’s Eliquis, Orencia, and Empliciti

By

Updated

Eliquis’s revenue trends

In 3Q17, Bristol-Myers Squibb’s (BMY) Eliquis generated revenues of $1.2 billion, a ~39% increase on a year-over-year (or YoY) basis and 5% growth on a quarter-over-quarter basis. In 3Q17, in the US market and in international markets, Eliquis generated revenues of $717 million and $515 million, respectively, compared to $512 million and $372 million in 3Q16.

Eliquis reported revenues of $3.5 billion during the first nine months of 2017 compared to $2.4 billion in the corresponding period of 2016. Eliquis is used to reduce the risk of stroke and systemic embolism in individuals with nonvalvular atrial fibrillation, as well as the prevention and treatment of deep vein thrombosis and pulmonary embolism.

Orencia revenue trends

In 3Q17, Orencia reported revenues of $632 million, a 10% increase on a YoY basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Orencia generated revenues of $432 million and $231 million, respectively, compared to $387 million and $185 million in 3Q16.

Orencia (abatacept) reported revenues of $1.8 billion during the first nine months of 2017 compared to $1.6 billion in the first nine months of 2016. Orencia is used for the treatment of adults with moderate to severe rheumatoid arthritis and psoriatic arthritis. Orencia is also used for the treatment of children aged two and above with moderately to severely active polyarticular juvenile idiopathic arthritis.

Orencia competes with Amgen’s (AMGN) Enbrel, Johnson & Johnson’s Simponi, Roche’s (RHHBY) Rituxan, and AbbVie’s (ABBV) Humira. In 3Q17, Enbrel, Rituxan, and Humira reported revenues of $1.4 billion, $1.8 billion, and $4.7 billion, respectively.

Empliciti revenue trends

In 3Q17, Empliciti reported revenues of $60 million, which reflected 46% growth on a YoY basis and 9% growth on a quarter-over-quarter basis. In 3Q17, in the US market and outside US markets, Empliciti generated revenues of $39 million and $21 million, respectively, compared to $36 million and $5 million in 3Q16.

Empliciti reported revenues of $168 million during the first nine months of 2017 compared to $103 million in the corresponding period of 2016. Empliciti, lenalidomide, and dexamethasone are used as a combination therapy to treat individuals with multiple myeloma who have undergone at least one to three previous therapies.

The growth in Bristol-Myers Squibb’s product sales could boost the share prices of the Vanguard Total Stock Market ETF (VTI). Bristol-Myers Squibb makes up about ~0.39% of VTI’s total portfolio holdings.

More From Market Realist